Imunon (IMNN) News Today $5.93 -0.10 (-1.66%) Closing price 04:00 PM EasternExtended Trading$6.06 +0.13 (+2.19%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementAugust 28 at 5:12 PM | finanznachrichten.deIMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementAugust 28 at 8:05 AM | globenewswire.comImunon, Inc. Advances Phase 3 Trial for Innovative Cancer TreatmentAugust 14, 2025 | msn.comImunon, Inc.’s Ongoing Clinical Trial: Potential Game-Changer for Ovarian Cancer Treatment?August 14, 2025 | tipranks.comIMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…August 8, 2025 | finance.yahoo.comImunon, Inc. Earnings Call Highlights Progress and ChallengesAugust 5, 2025 | tipranks.comImunon Q2 2025 Earnings PreviewAugust 5, 2025 | msn.com6IMNN : Insights into Imunon's Upcoming EarningsAugust 5, 2025 | benzinga.comImunon outlines rapid OVATION 3 Phase III trial launch and initiates 15% stock dividend to support shareholder valueAugust 5, 2025 | msn.comIMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference CallAugust 5, 2025 | globenewswire.comImunon, Inc. (IMNN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comIMUNON Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 5, 2025 | globenewswire.comImunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is UndervaluedJuly 30, 2025 | msn.comIMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?July 30, 2025 | benzinga.comIMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian CancerJuly 30, 2025 | globenewswire.comIMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025July 29, 2025 | globenewswire.comIMUNON Announces Stock Dividend Boosting Shareholder ValueJuly 28, 2025 | globenewswire.comImunon, Inc. Advances DNA Vaccine Study for COVID-19 VariantsJuly 25, 2025 | tipranks.comIMUNON Announces Reverse Stock SplitJuly 23, 2025 | globenewswire.comIMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance PlanJuly 15, 2025 | finance.yahoo.comIMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance PlanJuly 15, 2025 | globenewswire.comImunon, Inc. (IMNN) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comImunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market PerspectiveJuly 3, 2025 | tipranks.comImunon, Inc. Advances Phase II Study on IMNN-001 for Ovarian CancerJuly 3, 2025 | tipranks.comIMUNON Presents Positive Phase 2 Results For IMNN-001 In Advanced Ovarian Cancer At ESMO 2025June 20, 2025 | nasdaq.comIMNN: Translational Data from OVATION 2 Presented…June 20, 2025 | finance.yahoo.comIMUNON Reports Six-Month Durability and Manufacturing Benefits of PlaCCine® DNA Vaccine Technology Over mRNA Vaccines, Seeks Strategic PartnershipJune 18, 2025 | nasdaq.comIMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025June 18, 2025 | globenewswire.comIMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™June 17, 2025 | globenewswire.comImunon Appoints Kimberly Graper as Interim CFOJune 13, 2025 | tipranks.comIMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12thJune 6, 2025 | finance.yahoo.comASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancerJune 4, 2025 | finance.yahoo.comIMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 StudyJune 3, 2025 | globenewswire.comIMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers…June 2, 2025 | finance.yahoo.comIMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALSJune 2, 2025 | globenewswire.comImunon Inc. Faces Nasdaq Delisting Over Compliance IssuesJune 1, 2025 | uk.investing.comWhy Imunon, Inc. (IMNN) Surged Last WeekMay 31, 2025 | msn.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 29, 2025 | seekingalpha.comImunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M MoreMay 28, 2025 | insidermonkey.comIMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 28, 2025 | finance.yahoo.comImunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News SoonMay 27, 2025 | msn.comImunon announces up to $9.75M private placement priced at-the-marketMay 27, 2025 | finance.yahoo.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 27, 2025 | globenewswire.comIMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced ...May 25, 2025 | seekingalpha.comImunon shares soar on promising ovarian cancer trial resultsMay 23, 2025 | investing.comBiotech Stock Surges To Close The Week After Major AnnouncementMay 23, 2025 | msn.comIMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 23, 2025 | globenewswire.comImunon, Inc.: IMUNON Announces Withdrawal of Form S-1 Registration StatementMay 23, 2025 | finanznachrichten.deIMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian CancerMay 23, 2025 | globenewswire.comRetail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’May 23, 2025 | msn.com Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNN Media Mentions By Week IMNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNN News Sentiment▼0.961.03▲Average Medical News Sentiment IMNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNN Articles This Week▼32▲IMNN Articles Average Week Get the Latest News and Ratings for IMNN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Imunon and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CUE News Today IMMX News Today SLGL News Today ALGS News Today ALXO News Today IVVD News Today ADVM News Today ANL News Today IFRX News Today HOWL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access